GE HealthCare (GEHC) announced that the NCCN Clinical Practice Guidelines in Oncology for clinicians now recommend considering fluoroestradiol, FES, positron emission tomography, PET, for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare’s Cerianna injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive breast cancer metastases, including lobular breast cancer. The updated NCCN Guidelines expand the recommendation for the use of FES PET imaging in ER+ disease. In 2023, FES PET was included in the NCCN Guidelines for systemic staging of recurrent/stage IV ER+ breast cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE Healthcare Holds Annual Stockholders Meeting
- GE HealthCare management to meet with Oppenheimer
- Cautious Outlook for GE Healthcare Technologies Amid Trade Developments and Market Underperformance
- GE HealthCare sees revenue decline in Q2 ‘more’ than Q1
- GE HealthCare gets FDA approval for Optison ultrasound enhancing agent